Michael Dubriwny
Psychiatry · Tulsa, OKNPI 1659341808
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 589 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 589 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- Lundbeck LLC$888
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$769
- Sunovion Pharmaceuticals Inc.$652
- Johnson & Johnson$598
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,17598%
- Education$1502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 92 | $1,344 |
| AbbVie(2 entities) | 122 | $1,052 |
| Lundbeck LLC | 82 | $888 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $769 |
| Sunovion Pharmaceuticals Inc. | 41 | $652 |
| Johnson & Johnson | 31 | $598 |
| Alkermes, Inc. | 27 | $517 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $484 |
| Avanir Pharmaceuticals, Inc. | 24 | $399 |
| Teva Pharmaceuticals USA, Inc. | 11 | $274 |
| Axsome Therapeutics, Inc. | 8 | $225 |
| Jazz Pharmaceuticals Inc. | 14 | $218 |
| Eisai Inc. | 17 | $182 |
| Shire North American Group Inc | 8 | $121 |
| Vanda Pharmaceuticals Inc. | 8 | $114 |
| Supernus Pharmaceuticals, Inc. | 4 | $80 |
| Almatica Pharma LLC | 4 | $66 |
| Adlon Therapeutics L.p. | 4 | $55 |
| Orexo US, Inc. | 3 | $46 |
| Corium, LLC | 2 | $34 |
| Noven Therapeutics, LLC | 2 | $32 |
| Neos Therapeutics, LP | 2 | $32 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Indivior Inc. | 2 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Biogen | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,325 in reported general payments places this provider in the 90th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Guanfacine Hcl ErGuanfacine Hcl | 19 | $955 |
| Bupropion XlBupropion Hcl | 17 | $802 |
| Duloxetine Hcl | 18 | $709 |
| Lamotrigine | 11 | $251 |
| Gabapentin | 14 | $163 |
| Alprazolam | 16 | $85 |
| Trazodone Hcl | 12 | $84 |
| Olanzapine | 12 | $55 |
| Lorazepam | 13 | $53 |
| Clonidine Hcl | 14 | $32 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Tulsa
- Sarah LandTulsa$287K
- Bradley McClureTulsa$15K
- Katrina CraderTulsa$15K
- Jeffrey CatesTulsa$11K
- Kaitlin CoresTulsa$10K
- Charles van TuylTulsa$9K
- Martin PaulusTulsa$7K
- Joe SpeerTulsa$7K
- Kari YoumanTulsa$5K
- Stevan LahrTulsa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.